江苏恒瑞医药股份有限公司董事会 2026年11月19日 [1] Zhang L, Li YH, Wang DS, et al. Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2026;44(16_suppl):11006.